The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fezolinetant (Veoza®) has been rejected for use in the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Abaloparatide (Eladynos®) has been accepted for restricted use in the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The restriction limits use to patients at very high risk of fracture, assessed using a validated fracture risk assessment tool. This advice also applies only in the context of approved NHSScotland Patient Access Scheme and as such it would be expected that this item would be prescribed in secondary care.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.